Bioxcel therapeutics receives permanent j-code for igalmi™ (dexmedetomidine) sublingual film from centers for medicare & medicaid services

Standardizes and improves product reimbursement process new hcpcs level ii code j1105 to be effective january 1, 2024 new haven, conn., oct. 30, 2023 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the centers for medicare & medicaid services (cms) has issued a permanent and product-specific j-code for igalmi™ (dexmedetomidine) sublingual film, which is approved for the acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder in adults1,2.
BTAI Ratings Summary
BTAI Quant Ranking